

Applicants : Martin et al.  
USSN : 10/518,003  
Filed : 3-14-2005  
Examiner : Lawrence Crane  
Page : 3

Atty. Dkt. No. : 636-C-PCT-US  
Art Unit : 1623  
Date of office action: 4-4-2008  
Date of response : 8-4-2008

Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-70. (Canceled)

71. (New) A pharmaceutical composition comprising an effective amount of 6-methylmercaptopurine riboside (MMPR), 6-aminonicotinamide (6-AN), N-(phosphonacetyl)-L-aspartic acid (PALA), alanosine (AL), dehydroepiandrosterone (DHEA), and oxythiamine (OT), in combination with a pharmaceutically acceptable carrier.
72. (New) A pharmaceutical composition comprising an effective amount of 6-methylmercaptopurine riboside (MMPR), 6-aminonicotinamide (6-AN), N-(phosphonacetyl)-L-aspartic acid (PALA), alanosine (AL), and 4[(1E)-2-(1H-indol-3-yl)ethenyl]-1-methyl-pyridinium iodide, in combination with a pharmaceutically acceptable carrier.
73. (New) A pharmaceutical composition comprising an effective amount of N-(phosphonacetyl)-L-aspartic acid (PALA), alanosine (AL), 6-methylmercaptopurine riboside (MMPR), and 3-bromopyruvate (BrPA), in combination with a pharmaceutically acceptable carrier.
74. (New) The composition of claim 73, further comprising adriamycin.

Applicants : Martin et al.  
USSN : 10/518,003  
Filed : 3-14-2005  
Examiner : Lawrence Crane  
Page : 4

Atty. Dkt. No. : 636-C-PCT-US  
Art Unit : 1623  
Date of office action: 4-4-2008  
Date of response : 8-4-2008

75. (New) The composition of claim 74, wherein the amount of adriamycin is one-half the maximum tolerated dosage.
76. (New) A pharmaceutical composition comprising an effective amount of N-(phosphonacetyl)-L-aspartic acid (PALA), alanosine (AL), 6-methylmercaptopurine riboside (MMPR), dehydroepiandrosterone (DHEA), and oxythiamine (OT), in combination with a pharmaceutically acceptable carrier.
77. (New) A method for treating a subject having breast cancer, comprising administering to the subject the following agents:
- (i) N-(phosphonacetyl)-L-aspartic acid (PALA);
  - (ii) alanosine (AL);
  - (iii) 6-methylmercaptopurine riboside (MMPR); and
  - (iv) 3-bromopyruvate (BrPA).
78. (New) The method of claim 77, wherein the agents are administered concurrently or sequentially.
79. (New) The method of 77 further comprising administration of adriamycin.
80. (New) The method of 79, wherein the amount of adriamycin administered is one-half the maximum tolerated dosage.